# Registry Study for Talimogene Laherparepvec

> **NCT02173171** · — · COMPLETED · sponsor: **Amgen** · enrollment: 185 (actual)

## Conditions studied

- Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial

## Interventions

- **OTHER:** Information collection

## Key facts

- **NCT ID:** NCT02173171
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-27
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-09-23
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173171, "Registry Study for Talimogene Laherparepvec". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02173171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*